United Therapeutics
UTHR
303 hedge funds and large institutions have $4.66B invested in United Therapeutics in 2014 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 108 increasing their positions, 119 reducing their positions, and 40 closing their positions.
19% more call options, than puts
Call options by funds: $38M | Put options by funds: $32M
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
9% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 119
2% less funds holding
Funds holding: 308 → 303 (-5)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
40% less capital invested
Capital invested by funds: $7.74B → $4.66B (-$3.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
+$65.3M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$61.3M |
| 3 |
SCM
Scopia Capital Management
New York
|
+$58.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$34.8M |
| 5 |
GAM
Gotham Asset Management
New York
|
+$31.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.2B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$124M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$86.8M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$60.7M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$44M |
UTHR Hedge Fund Activity: Q2 2014 in Review
303 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2014, worth a combined $4.66B — down 40% from $7.74B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of UTHR and 38 opened new positions — a net loss of 2 holders — while 119 trimmed existing stakes and 108 added.
The largest buyer was Herndon Capital Management, adding an estimated $65.3M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $1.2B.
- 303 institutional investors held United Therapeutics (UTHR) as of Q2 2014, down from 308 in Q1 2014.
- Funds reported $4.66B of United Therapeutics stock for Q2 2014, down 40% quarter-over-quarter.
- 38 funds opened new United Therapeutics positions in Q2 2014 and 40 closed out, a net change of -2 holders.
- The largest United Therapeutics buyer in Q2 2014 was Herndon Capital Management, an estimated $65.3M added.
- The largest United Therapeutics seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $1.2B sold.
Based on aggregated 13F filings for Q2 2014.